CRISPR Therapeutics AG Stock Price and Value Analysis

CRISPR Therapeutics AG (NASDAQ:CRSP) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold CRISPR Therapeutics AG to reach your target.

Target type

CRSP Free Cash Flow Trend

Free Cash Flow trendline for CRSP
Free Cash Flow trendline for CRISPR Therapeutics AG

Hmm, we can't give any reliable projection for CRISPR Therapeutics AG's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

AdvantagesDisadvantagesNeutral
None.
  • This stock looks overpriced.
  • This company has wild ups and downs.
  • This company is not making money.
  • This company is less known than others.
  • This company pays no dividend.

Inside the CRSP Numbers

CRSP Price
(CRISPR Therapeutics AG stock price per share)
$46.54
[?] PE Ratio versus Sector 27% lower than other Healthcare stocks
[?] PE Ratio versus Industry 74% lower than other Biotechnology stocks
[?] Free Cash Flow Jitter 189%

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 19,808,194 shares shorted. With 96,037,920 shares available for purchase and an average trading volume over the past 10 trading days of 1,727,580, it would take at least 11.466 days for all of the short holders to cover their shorts.

What does this mean to you? At this volume, it'll take more than two trading weeks for shorts to cover. This may indicate a short squeeze play would work! If this stock has good fundamentals and it'll take a while for the short holders to cover, buying now could net you bigger short-term technical gains if and as the price rises.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

Price Versus Our Estimated Value

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in CRSP

Does CRISPR Therapeutics AG have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: CRSP

This example shows how we apply the Trendshare checklist to CRSP: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 46.54
    • Market cap: $4.6B
    • EPS: -6.17
  2. Step 2 — Valuation checks

    • P/E: —
    • FCF yield: —
    • Date checked: Jul 28, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.